10-Q: Quantum-Si Reports Q1 2026 Results Amid Proteus Development

Quantum-Si Incorporated reported its first quarter 2026 financial results, showing a significant decrease in revenue and gross profit, largely attributed to customers deferring purchases in anticipation of the upcoming Proteus platform launch.

Summary

• Quantum-Si Incorporated reported a net loss of $21.7 million for the first quarter ended March 31, 2026, compared to a net loss of $19.2 million for the same period in 2025.
• Total revenue decreased by 69.4% to $258,000 in Q1 2026 from $842,000 in Q1 2025, primarily due to lower instrument and consumable sales as customers await the Proteus platform.
• Gross profit margin declined to 28.7% in Q1 2026 from 57.7% in Q1 2025, influenced by product mix and lower sales volumes.
• Research and development expenses increased by 5.6% to $14.5 million, driven by efforts supporting the Proteus platform development.
• Selling, general, and administrative expenses decreased by 18.9% to $9.6 million, largely due to reduced legal fees.
• The company ended the quarter with $36.2 million in cash and cash equivalents and $154.2 million in marketable securities, totaling $190.4 million in liquidity.
• The company anticipates continued revenue impact in 2026 due to customer anticipation of the Proteus platform, expected to launch by the end of 2026.
• A legal settlement of $8.0 million was finalized, with $4.6 million covered by insurance proceeds.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the significant revenue decline and increased net loss, although the strategic rationale for the decline (Proteus platform development) offers a potential future upside.

Positives

• Increased cash and cash equivalents by $14.6 million to $36.2 million.
• Strengthened marketable securities position, with total marketable securities at $154.2 million.
• Reduced selling, general, and administrative expenses by $2.2 million, indicating cost management.
• Continued investment in research and development, with a 5.6% increase to support the development of the next-generation Proteus platform.
• Finalized a significant legal settlement, removing a contingent liability.

Negatives

• Net loss increased by $2.5 million to $21.7 million for the quarter.
• Total revenue decreased by 69.4% to $258,000.
• Gross profit margin significantly decreased to 28.7% from 57.7%.
• Inventory write-downs amounted to $1.3 million in R&D expenses.
• The company expects continued revenue impact in 2026 due to customer anticipation of the Proteus platform.

Risks

• The launch of the Proteus platform may not occur within the communicated timeframe or may not include the expected customer-focused applications and capabilities, which could materially impact long-term financial success and market credibility.
• The development and launch of new products, such as Proteus, may slow or delay customer purchasing decisions for existing instruments and consumables, adversely impacting revenue.
• The company has a history of significant losses and negative cash flows from operations, with an accumulated deficit of $719.7 million as of March 31, 2026.
• There is no assurance that the company will be able to obtain sufficient additional capital when needed, which could negatively impact its financial condition and ability to pursue its business strategy.
• The company may never achieve profitability.
• Global economic conditions, including inflation, interest rates, and supply chain disruptions, could adversely impact the business.
• Geopolitical conflicts could impact product and material availability and increasing costs.
• The company's ability to maintain the listing of its Class A common stock on The Nasdaq Stock Market LLC.
• Changes in applicable laws or regulations.
• The success, cost, and timing of product development and commercialization activities.
• The commercialization and adoption of existing and future products.
• The ability to obtain and maintain regulatory approval for products.
• The ability to identify, in-license, or acquire additional technology.
• The ability to maintain existing lease, license, manufacture, and supply agreements.
• Competition from companies with greater financial and marketing resources.
• The size and growth potential of the markets for its products and services.
• Estimates regarding future expenses, revenue, capital requirements, and needs for additional financing.

Future Outlook

The company expects revenue in 2026 to continue to be impacted as customers may delay purchases ahead of the Proteus platform becoming commercially available by the end of 2026. Management believes the company's cash, cash equivalents, and marketable securities will be sufficient to fund planned operations for at least the next twelve months. Future operations are expected to be financed through private and public equity offerings, debt financings, and potential collaboration, license, and development agreements.

Management Comments

• Management believes the company's cash, cash equivalents and marketable securities, together with revenue from the sales of its products and services, will be sufficient to fund its planned operations for at least the next twelve months.
• We expect revenue in 2026 to continue to be impacted as customers may delay purchases ahead of Proteus becoming commercially available by the end of 2026.
• We expect gross profit margin to be variable for the foreseeable future as we work through our continued commercialization efforts.
• We expect operating cash usage to continue to be impacted by operating results and working capital requirements.
• We expect to incur negative operating cash flows on an annual basis for the foreseeable future until such time that we can scale our revenue growth.

Industry Context

StockSavvy.ai notes that Quantum-Si's Q1 2026 results reflect a common challenge for companies developing disruptive technologies: the 'pre-launch dip' in sales as customers anticipate new product releases. The significant revenue decline, while concerning, is directly linked to the strategic development and anticipated launch of their next-generation Proteus platform, a move that could redefine their market position if successful.

Comparison to Industry Standards

• Companies in the life sciences tools sector often experience revenue fluctuations related to product development cycles and new technology introductions.
• The decline in gross profit margin is a concern, but it is presented in the context of a strategic shift towards a new product launch, which can temporarily impact margins.
• The R&D spending increase aligns with industry trends for companies investing heavily in innovation to maintain a competitive edge in the rapidly evolving proteomics market.
• Competitors like Thermo Fisher Scientific and Agilent Technologies also invest heavily in R&D and face similar challenges in managing product lifecycles and market transitions.

Legal Proceedings

• Delaware Stockholder Litigation: A class action lawsuit alleging breach of fiduciary duty related to the Business Combination. A preliminary settlement was reached, and the Delaware Court of Chancery approved the final settlement on March 27, 2026. The company recorded an $8.0 million liability, with $4.6 million covered by insurance.

Related Party Transactions

• Amended and Restated Technology Services Agreement (ARTSA) with 4Catalyzer Corporation and other participant companies controlled by Dr. Jonathan Rothberg. The company's participation terminated prior to the Business Combination. There were no expenses paid to 4C for the three months ended March 31, 2026, compared to $0.1 million in the prior year period for sublease arrangements and administrative services.

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings; potential long-term value creation if the Proteus platform is successful; current financial performance is negative.
• Employees: Continued investment in R&D may lead to job security and growth opportunities, but the company's financial performance could pose risks.
• Customers: May defer purchases of existing products in anticipation of the Proteus platform, impacting their immediate research timelines.
• Suppliers: Potential impact from changes in material availability and costs due to global economic factors.
• Creditors: The company's ability to secure future financing is crucial for its ongoing operations.

Next Steps

• Continue development and commercialization of the Proteus TM platform, with an anticipated launch by the end of 2026.
• Manage operating expenses and working capital requirements.
• Monitor global economic conditions, including inflation and interest rates.
• Continue to manage the investment portfolio to optimize liquidity.
• Potentially pursue future equity or debt offerings to fund operations.

Key Dates

Recommendation

The company is in a critical development phase with its Proteus platform, which holds significant future potential. However, the current financial results show a substantial decline in revenue and an increase in net loss, directly linked to customer anticipation of this new technology. While the company maintains a strong liquidity position, the near-term outlook is challenging due to the expected revenue impact. Investors should hold their position, awaiting further clarity on the Proteus launch and its market reception, while acknowledging the inherent risks and the potential for future growth.

Keywords

Quantum-Si, 10-Q, Proteomics, NGPS, Single-molecule analysis, Proteus platform, Platinum Pro, Financial Results, SEC Filing, Life Sciences